The Middle East and Africa (MEA) region is vast and is predominantly composed of emerging countries with varying levels of income and healthcare infrastructure. Here, three regional managers for pharma…
Amgen MEA’s Mohamed Nasser* examines the current pharma commercialisation model, posits how the entire healthcare ecosystem’s rapid and effective response to COVID-19 could be replicable in other disease areas, and…
Saudi Chemical Company Holding (SCCH), Saudi Arabia’s leading manufacturer of civil and military explosives, has been expanding its pharma sector footprint in recent years. Today, the company has capabilities across…
Seasoned executive Mohamed Nasser currently oversees 16 markets for Amgen across the MEA region, including its most important – Saudi Arabia. He shares some of the key skills that pharma…
As of today, the Evergreen boat that blocked global shipping when it got stuck in the Suez Canal has still not been allowed to leave Egypt. The infamous episode illustrated…
As Egypt rolls out Universal Health Insurance with the aim of achieving full coverage between 2030 and 2035, the domestic pharmaceutical market stands to see significant long-term shifts. As self-medication…
With an already well-established manufacturing industry for pharmaceuticals, Turkey has been aiming to move with global trends and invest in biologics production, specifically in biosimilars. The share of biotechnological…
Becoming the clinical trials country leader in the region has been set as a primary goal for Turkey’s pharma industry to achieve global competitiveness. The government’s strategy is to increase…
See our Cookie Privacy Policy Here